Located in Columbia, Missouri, IMMVAC INC. manufactures vaccines and serums to aid in the prevention and treatment of virtually all Gram-negative bacterial diseases of production and companion animals.
IMMVAC Technology
The IMMVAC INC. products are based on two proprietary technologies:
Re-17, Core Antigen
The patented, genetically-engineered Gram-negative bacterin, Re-17, is comprised of the universal core antigen common to all Gram-negative bacteria;
E3, IMMUNE Plus®
The patented immunopotentiator, E3 or IMMUNE Plus®, stimulates production of B and T lymphocytes, thereby enhancing an animals overall immunity to disease.
